The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10355
A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies
Dana-Farber – Harvard Cancer Center LAO
Lee, Elizabeth Katherine
(617) 632-5269
Phase I – A051901
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Alliance for Clinical Trials in Oncology
Alencar, Alvaro Jose
(305) 243-4372
Phase II – EA3191
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
ECOG-ACRIN Cancer Research Group
Zandberg, Dan Paul
(412) 864-7955
Phase II – PEPN1924
A Phase 2 Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Pediatric Early Phase Clinical Trial Network
Reed, Damon Russell
(813) 745-3242
Phase III – ACNS1931
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Children’s Oncology Group
Bowers, Daniel Charles
(214) 648-3896
Phase Other – A152022
Alliance COVID-19 Pandemic Study
Alliance for Clinical Trials in Oncology
Hahn, Olwen Mary
(773) 702-4400
Phase Other – S1912CD
A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
SWOG
Shankaran, Veena
(206) 288-7456
Phase Pilot – PEPN21EHRPBTCN15
Pilot Study to Enable Electronic Laboratory Data Transfer Into Medidata Rave
Pediatric Early Phase Clinical Trial Network
Miller, Tamara Porter
(404) 727-9268
